ZL-1310 for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ZL-1310 for individuals with relapsed Small Cell Lung Cancer (SCLC). Researchers aim to determine if ZL-1310 is more effective and safer than other treatments chosen by doctors. The study consists of two parts: one group will receive ZL-1310, while the other will receive a treatment selected by their doctor. Candidates may qualify if they have SCLC that has progressed after previous treatments and are willing to provide a tumor sample. As a Phase 3 trial, this study is the final step before FDA approval, offering participants the chance to contribute to the potential availability of a new treatment option.
Is there any evidence suggesting that ZL-1310 is likely to be safe for humans?
Research has shown that ZL-1310 has been safe for participants in earlier studies. In past trials, participants experienced manageable side effects, indicating that most tolerated the treatment well. Importantly, ZL-1310 proved effective against tumors, including those in the brain. These results suggest that ZL-1310 could be a promising option for individuals with relapsed Small Cell Lung Cancer. While all treatments can have side effects, evidence so far indicates that ZL-1310 is relatively safe for humans.12345
Why do researchers think this study treatment might be promising for lung cancer?
ZL-1310 is unique because it potentially offers a new approach to treating lung cancer by acting as a single-agent therapy. Unlike most standard treatments that involve chemotherapy or targeted therapies, ZL-1310 could target cancer cells through a different mechanism, providing an alternative for patients who may not respond well to existing options. Researchers are excited about ZL-1310 because it could improve outcomes for patients with fewer side effects and offer a novel mechanism of action that might be more effective against certain types of lung cancer cells.
What evidence suggests that ZL-1310 might be an effective treatment for lung cancer?
Research has shown that ZL-1310 offers promising results for treating small cell lung cancer. In a study with 102 patients, almost half (47%) experienced a confirmed response, with tumors shrinking or disappearing. These effects lasted an average of 6.1 months. The treatment also effectively targeted brain tumors while maintaining manageable side effects. In this trial, participants will receive either ZL-1310 as a single agent or an investigator's choice of therapy. These findings suggest ZL-1310 could be a strong option for patients whose small cell lung cancer has returned.12346
Are You a Good Fit for This Trial?
This trial is for adults with relapsed Small Cell Lung Cancer who've had previous platinum-based therapy and progressed during or after treatment. They must have measurable disease, stable brain metastases if present, good organ function, an ECOG performance status of 0 or 1, and a life expectancy of at least three months.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either ZL-1310 or Investigator's Choice Therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ZL-1310
Trial Overview
The study compares the effectiveness and safety of ZL-1310 to treatments chosen by the investigators (standard options) in patients with relapsed Small Cell Lung Cancer. Participants will be randomly assigned to receive either ZL-1310 or a standard therapy.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
ZL-1310 as a single agent
Investigator's Choice of Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zai Lab (Shanghai) Co., Ltd.
Lead Sponsor
Zai Lab (US) LLC
Industry Sponsor
Citations
1.
ir.zailaboratory.com
ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-updated-phase-1-data-zocilurtatug-pelitecanZai Lab Announces Updated Phase 1 Data for Zocilurtatug ...
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class ...
ZL-1310, a DLL3 ADC, in patients with extensive stage ...
Median age was 66 years (range 36-79); 43% were female; 75% had an ECOG performance status of 1; 93% progressed after prior anti-PD-L1 therapy; ...
NCT07218146 | A Study of ZL-1310 Versus Investigator's ...
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with ...
4.
aacrjournals.org
aacrjournals.org/cancerdiscovery/article/16/1/OF1/771332/ADC-for-SCLC-Clears-Phase-IADC-for-SCLC-ClearsADC for SCLC Clears Phase I | Cancer Discovery
Among the 102 evaluable patients, 48 (47%) achieved a confirmed objective response. The median duration of response was 6.1 months, and median ...
5.
ir.zailaboratory.com
ir.zailaboratory.com/news-releases/news-release-details/zai-lab-presents-positive-phase-1-data-zl-1310-dll3-targeted-adcZai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3 ...
The updated Phase 1 results for ZL-1310 show strong anti-tumor activity, including intracranial responses with a manageable safety profile.
Investigational Antibody-drug Conjugate Shows Clinical ...
BOSTON – Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.